Resolve Therapeutics Raises $5.8M to Help Lupus Patients
November 2, 2012
Resolve Therapeutics, a biotech company focused on innovative treatments for patients with lupus, has raised $5.8 million in Series B financing. Leading the round was previous investor New Science Ventures, a VC firm that commonly invests in the life sciences sector. WRF Capital, a new investor, and Eastern Capital also participated in the round.